BioStack Raises $9.5 Million in Funding Led by Peak XV and DCVC
Healthcare technology startup BioStack has raised $9.5 million in seed funding to expand its clinical data infrastructure and support the development of artificial intelligence (AI) models for healthcare and medical research. The company announced the funding round on October 22, 2026, with Peak XV and Afore Capital as lead investors, alongside DCVC and other backers.
The Y Combinator-backed startup aims to address a major challenge in healthcare AI development: accessing and connecting high-quality clinical data across different healthcare systems.
BioStack’s $9.5 Million Funding Round
BioStack’s latest funding round includes investments from Peak XV, Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures, and Y Combinator. The company plans to use the capital to expand its presence in the United States and international markets, strengthen its technology platform, and grow its engineering and research teams.
The investment reflects the growing interest in healthcare data infrastructure, particularly solutions that help researchers and technology companies develop and evaluate AI models using real-world clinical information.
How BioStack Is Transforming Healthcare Data
Healthcare information is often distributed across hospitals, laboratories, medical imaging systems, and electronic health records. This fragmentation can make it difficult for researchers to understand how diseases progress, how treatments affect patients, and which factors influence medical outcomes.
BioStack connects fragmented clinical information to create longitudinal patient records. Its platform brings together different types of healthcare data, including clinical notes, laboratory results, medical imaging, medications, treatment histories, and patient outcomes.
According to the company’s announcement, its network spans the United States, India, Brazil, and Argentina, with access to more than 100 million de-identified patient records.
By organising this information into usable datasets, BioStack aims to help AI developers and biotechnology companies build, train, and evaluate healthcare models more effectively.
Supporting Medical AI and Clinical Research
Access to relevant clinical data is essential for developing healthcare AI systems that can assist with complex medical research and decision-making. BioStack’s infrastructure is designed to support several applications, including medical AI model development, clinical research, disease modelling, biomarker discovery, patient stratification, and treatment-response analysis.
The platform can help researchers study relationships between medical conditions, treatments, and patient outcomes. It can also provide datasets for evaluating how AI models perform across different clinical scenarios.
However, the quality and usefulness of these datasets depend on factors such as data completeness, appropriate permissions, patient privacy safeguards, and the relevance of the information to each research application.
BioStack’s Global Expansion Plans
With operations spanning the United States, India, Brazil, and Argentina, BioStack is building a healthcare data network across multiple markets. Its international reach provides opportunities to work with diverse healthcare systems and patient populations.
The newly raised capital will support further expansion, continued platform development, and additional hiring across engineering and research functions.
As healthcare organisations and biotechnology companies explore new applications for AI, infrastructure that makes clinical information more accessible and useful for research could play an important role in the development of future medical technologies.
What BioStack’s Funding Means for Healthcare Technology
BioStack’s $9.5 million seed funding round highlights the importance of data infrastructure in the healthcare technology sector. While advances in AI models continue to attract attention, access to reliable, relevant, and appropriately governed clinical data remains a critical part of developing useful medical AI applications.
By connecting fragmented patient records and creating datasets for research and model evaluation, BioStack aims to support healthcare innovation and medical research.
The company’s next phase of growth will focus on expanding its global network, improving its technology platform, and strengthening its research and engineering capabilities as demand for healthcare AI infrastructure continues to grow.